NNVC (Nanoviricides) Cash Ratio: 3.02 (As of Mar. 2026) — 24% Below Median


NNVC Nanoviricides Inc NNVC
35 GF Score
Price $1.51
View Full Analysis

What is Nanoviricides Cash Ratio?

Nanoviricides NNVC -6.21% 35 Cash Ratio is 3.02 as of Mar. 2026, which is 24% below its 10-year median of 3.96. GuruFocus rates NNVC with a GF Score™ of 35/100. Among 1,386 Biotechnology companies, Nanoviricides ranks better than 50.72% on this metric.

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Nanoviricides's Cash Ratio for the quarter that ended in Mar. 2026 was 3.02.

Nanoviricides has a Cash Ratio of 3.02. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Nanoviricides's Cash Ratio or its related term are showing as below:

NNVC' s Cash Ratio Range Over the Past 10 Years
Min: 0.18   Med: 3.96   Max: 58.45
Current: 3.02

During the past 13 years, Nanoviricides's highest Cash Ratio was 58.45. The lowest was 0.18. And the median was 3.96.

NNVC's Cash Ratio is ranked better than
50.72% of 1386 companies
in the Biotechnology industry
Industry Median: 2.93 vs NNVC: 3.02

Nanoviricides  (AMEX:NNVC) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Nanoviricides Cash Ratio Related Terms


Nanoviricides Cash Ratio Historical Data

* Premium members only.

The historical data trend for Nanoviricides's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanoviricides Cash Ratio Chart

Nanoviricides Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 58.45 34.06 15.26 3.53 1.19

Nanoviricides Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.12 1.19 0.95 4.31 3.02

NNVC vs LSTA, SGMO, LITS: Cash Ratio Comparison

For the Biotechnology subindustry, Nanoviricides's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanoviricides Cash Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanoviricides's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Nanoviricides's Cash Ratio falls into.


NNVC
35GF Score
Nanoviricides Inc NNVC
Cash Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nanoviricides Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Nanoviricides's Cash Ratio for the fiscal year that ended in Jun. 2025 is calculated as:

Cash Ratio (A: Jun. 2025 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=1.559/1.307
=1.19

Nanoviricides's Cash Ratio for the quarter that ended in Mar. 2026 is calculated as:

Cash Ratio (Q: Mar. 2026 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=3.213/1.065
=3.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash Ratio →
What does a Cash Ratio of 3.02 mean?
Nanoviricides (NNVC) has a Cash Ratio of 3.02 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Nanoviricides and its competitors. This is 24% below median its historical median of 3.96. Over the past decade, Nanoviricides' Cash Ratio has ranged from 0.18 to 58.45. According to the industry distribution chart, Nanoviricides ranks #683 out of 1386 companies in the Biotechnology industry, placing it in the top 49.3%.
Is Nanoviricides' Cash Ratio too high?
Nanoviricides' current Cash Ratio of 3.02 is 24% below median its 10-year median of 3.96. Over the past 10 years, this metric has ranged from a low of 0.18 to a high of 58.45. The Biotechnology industry median Cash Ratio is 2.93. Nanoviricides' value of 3.02 is 3.1% above this industry median. Based on the distribution chart, Nanoviricides ranks #683 out of 1386 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Nanoviricides has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Nanoviricides' Cash Ratio compare to LSTA and SGMO?
According to the Biotechnology industry distribution chart, Nanoviricides ranks #683 out of 1386 companies for Cash Ratio. This puts Nanoviricides in the upper half of its industry. The industry median Cash Ratio is 2.93. Nanoviricides' value of 3.02 is 3.1% above this benchmark. Historically, Nanoviricides' own Cash Ratio has ranged from 0.18 to 58.45 over the past decade. While the company's 10-year median is 3.96 vs. the industry median of 2.93, Nanoviricides has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,386 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanoviricides's current Cash Ratio of 3.02 is 3.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Nanoviricides and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanoviricides's current Cash Ratio is 3.02, which is 24% below median its own 10-year median of 3.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanoviricides stock overvalued right now?
Nanoviricides (NNVC) has a current Cash Ratio of 3.02. The current Cash Ratio is 3.02, which is 24% below median its 10-year median of 3.96 and 3.1% above the Biotechnology industry median of 2.93. Nanoviricides' overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Nanoviricides (NNVC), the current Cash Ratio is 3.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nanoviricides Business Description

Other Exchanges NV3P:Germany
Address 1 Controls Drive, Shelton, CT, USA, 06484
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
35GF Score

Get the complete analysis for NNVC

Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.51
Price